Drugs / NK105
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01644890 | Jul 2012 → Jul 2016 | breast cancer | Nippon Kayaku Co., Ltd. | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NK105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01644890 ↗ |
| Modality | Other / unclassified | “NK105 is a novel nanoparticle drug delivery formulation” PMID 30745582 ↗ Feb 2019 |
| Route | Intravenous | “IV, Weekly” NCT01644890 ↗ |